National Bank of Canada
IBRX icon

National Bank of Canada’s ImmunityBio IBRX Stock Holding History

National Bank of Canada’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.67M Buy
608,774
+524,074
+619% +$3.59M ﹤0.01% 876
2025
Q4 		$168K Sell
84,700
-22,700
-21% -$51.4K ﹤0.01% 1637
2025
Q3 		$264K Buy
107,400
+98,400
+1,093% +$253K ﹤0.01% 1479
2025
Q2 		$23.8K Buy
+9,000
New +$24.2K ﹤0.01% 2139
2025
Q1 		– Sell
-490,300
Closed -$1.49M – 2979
2024
Q4 		$1.26M Buy
490,300
+405,900
+481% +$1.69M ﹤0.01% 1267
2024
Q3 		$314K Sell
84,400
-178,900
-68% -$828K ﹤0.01% 1297
2024
Q2 		$1.65M Buy
263,300
+207,989
+376% +$1.37M ﹤0.01% 964
2024
Q1 		$449K Buy
+55,311
New +$250K ﹤0.01% 1263
2023
Q4 		– Sell
-699,300
Closed -$1.07M – 2800
2023
Q3 		$1.07M Sell
699,300
-96,100
-12% -$193K ﹤0.01% 1184
2023
Q2 		$2.18M Buy
795,400
+663,300
+502% +$1.88M ﹤0.01% 972
2023
Q1 		$240K Hold
132,100
– – ﹤0.01% 1367
2022
Q4 		$670K Buy
132,100
+130,300
+7,239% +$716K ﹤0.01% 1196
2022
Q3 		$9K Hold
1,800
– – ﹤0.01% 2212
2022
Q2 		$7K Hold
1,800
– – ﹤0.01% 2351
2022
Q1 		$10K Hold
1,800
– – ﹤0.01% 2385
2021
Q4 		$11K Buy
+1,800
New +$13.5K ﹤0.01% 2325

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

National Bank of Canada's IBRX Position: Q1 2026 in Review

National Bank of Canada increased its ImmunityBio (IBRX) stake by 619% in Q1 2026, buying an estimated $3.59M and bringing the position to 608,774 shares worth $4.67M. The position accounts for ﹤0.01% of the portfolio, ranked #876.

National Bank of Canada first reported a position in IBRX in Q4 2021 and has held it in 16 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • National Bank of Canada held 608,774 shares of ImmunityBio worth $4.67M as of Q1 2026.
  • National Bank of Canada bought 524,074 ImmunityBio shares in Q1 2026, an estimated $3.59M.
  • ImmunityBio made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #876 holding.
  • National Bank of Canada first reported a position in ImmunityBio in Q4 2021 and has held it in 16 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.